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Abstract
This review focuses on the contributions made by interactions
between dendritic cells (DCs) and T cells, and by local production
of cytokines and chemokines to the pathogenesis of rheumatoid
arthritis (RA) synovitis. DCs are efficient professional antigen-
presenting cells, which are critical for the development of innate
and adaptative immune responses through interactions with
T cells. Cytokines from DCs play a key role in the switch inside
effector T-cell pathways. Chemokines are important mediators of
the immune response because they regulate leucocyte recruitment
to tissue, and they play a key role in inflammatory diseases by
acting on T-cell and DC migration. Furthermore, the recently dis-
covered T-helper-17 proinflammatory cytokines, present in syno-
vium samples, are associated with the migration, differentiation and
maturation of inflammatory cells, and they facilitate a network of
interactions between all components of the immune response. An
understanding of such interactions is essential because it is the
key to therapeutic application.
Introduction
For many years, research into rheumatoid arthritis (RA) has
focused on attempts to identify a causative agent, functionally
defined as an arthritogenic antigen [1], but this research has
thus far failed to yield new treatments. However, major
progress was recently made with use of inhibitors of tumour
necrosis factor (TNF)-α [2], a cytokine that is mainly
produced by monocytes/macrophages, with various effects in
many cell types. The gap between these two extreme
approaches - a causative (auto)antigen and a pleiotropic
cytokine - has now been reduced through the use of new
biotherapies that act on B and T cell targets.
This review discusses the contributions made by T cells and
antigen-presenting cells (APCs) to RA synovitis. These cells
interact through cell contacts and the release of cytokines
and chemokines. They further interact with local mesen-
chymal cells, namely synoviocytes. Dendritic cells (DCs) play
a central role in the development of innate and adaptive
immune responses [3]. Both mature and immature DCs have
been identified in the lymphocytic infiltrates of the RA
synovium, reflecting an ongoing immune-mediated reaction
[4]. The review does not consider the possible antigen
specificity of the response or the specific role played by B
cells, apart from their interactions with T cells.
Role of T cells in rheumatoid arthritis
The accumulation of many T cells in RA synovitis has been
recognized for many years. However, whether they played a
role in the pathogenesis of RA could not immediately be
determined for several reasons. The first obstacle was the
difficulty in detecting IFN-γ, which was then considered to be
the most characteristic T-cell-derived cytokine. Based on
these findings, the question ‘How important are T cells in
arthritis?’ was asked [5]. Similarly, IL-4 could not be detected
locally. Because IL-4 was also found to have anti-
inflammatory and anti-destructive effects, the lack of IL-4 in
RA could explain how a chronic inflammatory disease could
lead to destruction [6]. Further evidence against a role for
T cells was the lack of efficacy of treatment with anti-CD4
monoclonal antibodies. Various explanations were proposed
to explain the accumulation of numerous T cells in the
synovium without their playing a clear role in the disease.
On the other hand, classical arguments supported a role for
T cells, for example the link with the major histocompatibility
complex (MHC) class II DR4/DR1 association and the
transfer of disease with isolated T cells in animal models.
More recently, many of the key genes identified by genomic
screening are T-cell related, including the MHC shared
epitope association, PTPN22 and granzymes. Finally, abata-
cept was found to be able to control RA signs and symptoms
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by acting on cytotoxic T-lymphocyte antigen (CTLA)4, which
is expressed by T cells.
Characteristics of rheumatoid arthritis synovitis
The normal synovium is poorly infiltrated by immune cells. RA
synovitis is characterized by a massive infiltration with cells that
have migrated from blood. Mononuclear cells, consisting of
various subsets of DCs, monocytes, T cells and B cells,
accumulate in perivascular areas, with T cells being the most
prominent subset. The migration of these immune cells results
from vascular changes in endothelial cells of high endothelium
venules. Conversely, neutrophils are not present in the synovium
but accumulate in the synovial fluid in a less controlled manner.
Involvement of the microvasculature is also suggested by
phenotypical changes in vessels, with strong expression of
proinflammatory cytokines and of adhesion molecules by
endothelial cells. This favours the migration of subsets of T cells
and DCs expressing synovium-specific adhesion molecules on
their surface. This extravasation is followed by their
accumulation around vessels as perivascular infiltrates.
For some time RA synovitis was considered to represent a
lymphoid organ located in an ectopic position. Although RA
synovitis has retained the key structural features of normal
lymphoid organs, such as lymph nodes with germinal centres,
differences have been identified in cell subsets, in markers of
DC maturation and in the structure of the germinal centres.
These differences might be critical for our understanding of
the pathogenesis of RA.
Dendritic cells in rheumatoid arthritis
synovium tissue
DCs are very efficient professional APCs [3]. They play a unique
role in initiating immunity through the activation of naïve T cells
and support local immune responses by the attraction,
accumulation and activation of both CD4+ helper T cells and
CD8+ cytotoxic T lymphocytes. During maturation, DCs
undergo changes in phenotype, expressing long dendrites with
an upregulation of co-stimulatory and MHC class II molecules.
At the same time, DCs switch from an antigen-capturing cell
into an APC that can activate antigen-specific T cells. Cytokines
such as IL-1, TNF-α and granulocyte-macrophage colony-
stimulating factor, combined with IL-4, are known to contribute
to DC maturation [7]. Indeed, these cytokines are used in
sequential combination to obtain ex vivo mature functional DCs
from blood monocytes. Out of this list of cytokines, only IL-4 is
considered not to be produced by RA synovitis [8].
Two main types of DCs that mediate distinct biological
outcomes are distinguished by their lineage origin: myeloid
DCs and plasmacytoid DCs. Myeloid DCs are potent APCs
of the adaptive immune system, which stimulate lymphocytes
that are capable of highly specific immune responses.
Plasmacytoid DCs play an important role in innate immunity,
specifically in the control of viruses through their ability to
produce large amounts of type I IFNs (IFN-α and IFN-β).
In RA synovitis, both mature DCs (defined as CD1a-positive
cells) and immature DCs (defined as DC-LAMP [lysosomal-
associated membrane protein]-positive cells) are localized in
perivascular infiltrates [4]. Immature DCs express CD1a and
CC chemokine receptor (CCR)6, which is the receptor for
the chemokine CC chemokine ligand (CCL)20. Mature
myeloid DCs are characterized by the expression of CD86,
DC-LAMP and CCR7, which is the receptor for the
chemokines CCL19 and CCL21. Plasmacytoid DCs in RA
are found in perivascular lymphocytic infiltrates [9]. However,
the relative contribution of IFN-α produced by these cells in
RA is still unclear.
When RA synovium is compared with normal lymphoid tissue
such as tonsils or, even better, with activated lymph nodes
from the same patient, differences in maturation are
observed. The mature/immature DC ratio, defined by the
CD1a/DC-LAMP ratio, was lower than that in activated lymph
nodes from the same RA patients, which suggests a relative
accumulation of more immature DCs in the RA synovium [10].
Conversely this could result from defects in the maturation of
DCs because of improper cell interactions or changes in the
cytokine milieu, including lack of IL-4. Thus, changes in the
local cytokine profile could contribute to the DC maturation
defects. Inadequate maturation could in turn contribute to the
chronicity of the disease. In addition, blood-derived DCs from
RA patients exhibit increased expression of various Toll-like
receptors, resulting in increased production of proinflammatory
cytokines [11].
Taken together, these findings demonstrate the abnormal
accumulation of DCs in RA synovium, which reflects an
ongoing immune-mediated reaction that may lead to chronicity.
Cytokines from dendritic cells and effects on
the T-cell response
In RA synovium, most studies have demonstrated strong
expression of proinflammatory cytokines, mainly produced by
activated macrophages, monocytes and DCs. These cyto-
kines, in particular TNF-α, IL-1 and IL-6, participate in mono-
nuclear cell recruitment by inducing broad expression of
chemokines and by upregulating adhesion molecule expres-
sion on endothelial cells. The role played by these cytokines
was well established by successful therapeutic use of cyto-
kine inhibitors [2].
DCs are themselves the source of regulatory cytokines.
These cytokines affect the immune response by inducing
changes in the T-cell subsets. In turn, activation of these
subsets will induce a switch in the final immune response.
Plasmacytoid DCs are critical for the control of innate
immunity through the production of IFN-α. However, IFN-α
has been more directly associated with the pathogenesis of
lupus than that of RA [12]. However, a subset of RA patients
has been shown to express a pattern of genes that reflects
the contribution made by IFN-α [13]. It is unclear at this stagePage 3 of 6
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whether these patients have a specific disease presentation,
in particular with reduced joint destruction, as is observed in
arthritis associated with lupus.
DCs are also a source of key cytokines that strongly affect
the type of immune response in T cells. Such production will
then influence the selected T-helper (Th) pathway. IL-12 is
the key cytokine for the induction of the Th1 pathway leading
to the production of IFN-γ [14]. IL-12 acts in synergy with
IL-18, in which IL-12 induces the expression of the two α and
β chains of the IL-18 receptor [15]. This allows an increased
response to the combination of IL-12 and IL-18, leading to
massive IFN-γ production (Figure 1).
IL-23 is a new member of the IL-12 family, which was recently
described as a cytokine produced by monocytes and DCs
(Figure 1) [14]. In the mouse, at least, IL-23 is a key cytokine
for the induction of the Th17 pathway and production of IL-17
[16]. The involvement of IL-23 in RA synovium has yet to be
clarified, although its role in humans might be different from
that in mouse [17].
Production of cytokines by T cells and the Th
classification of rheumatoid arthritis
The link between T cells and the production of their asso-
ciated cytokines has been going through recent changes.
Because RA was associated with chronic inflammation and
destruction, it was classified as a Th1 disease, or at least as a
non-Th2 disease (Figure 1). The Th1/Th2 concept must now
be revisited to take into account the recently described Th17
cells [18,19]. The production of IL-17 by human T cells was
demonstrated long before the concept of a new T-cell lineage
producing IL-17 emerged from findings in mouse [20,21]. It
was shown much earlier that RA synovium could produce
functional IL-17 that can induce an inflammatory pattern in RA
synoviocytes [22]. At the same time, it was also established
that that some T-cell clones from RA synovium producing IL-
17 could represent a different subset of T cells [23].
Immunostaining of RA synovium biopsies reveals expression
of IL-17 in areas rich in T lymphocytes, whereas normal and
osteoarthritis samples are negative. In RA synovitis, IL-17
producing cells are identified as large cells with a plasma-
cell-like appearance. These cells are fully differentiated cells,
and their major function is to produce a single cytokine.
Coincident with their acquisition of this phenotype, they lose
their T-cell receptor/CD3 complex, thus becoming insensitive
to further antigen stimulation [24]. Although both Th1 and
Th17 cells induce matrix destruction and inhibit its formation,
Th17 cells make a more important contribution to inflam-
matory diseases, combining tissue destruction and absence
of repair [25].
Available online http://arthritis-research.com/supplements/10/S1/S2
Figure 1
Role of cytokines in DC and T-cell interactions. Dendritic cells (DCs) produce IL-12 and IL-18; these favour the T-helper (Th)1 pathway, which is
characterized by the transcription factor T-bet and the production of IFN-γ. The Th17 pathway results from the combined action of transforming
growth factor (TGF)-β plus IL-6 and of IL-23. This pathway is characterized by the transcription factor retinoid-related orphan receptor (ROR)γt and
by the production of IL-17. The effector Th1 and Th17 pathways are under the control of the regulatory pathway that is characterized by the
transcription factor FoxP3 and the production of TGF-β and IL-10. Defects in this pathway may contribute to the consequences of the chronic RA
synovitis that leads to destruction and lack of repair. It should be noted that some of these concepts have been established in the mouse; it is
unclear to what extent they apply to humans.A key property of IL-17 is its increased proinflammatory effect
when it is combined with TNF-α or IL-1 [25]. A synergistic
effect on IL-6 production between IL-1, TNF-α and IL-17 was
first demonstrated in synoviocytes. In addition, IL-17
increases the production of IL-1 and TNF-α by monocytes,
thus amplifying the inflammatory response. Conversely, the
Th17 and Th2 pathways inhibit each other’s functions,
suggesting a role for IL-17 in the absence of IL-4 described
above. In addition, at least in mouse, the combination of IL-6
and transforming growth factor-β favours the Th17 pathway,
but it has inhibitory effects on the function of regulatory T
cells [19]. Regulatory T cells express the transcription factor
Foxp3 and control effector T cells through cell contacts and
the release of transforming growth factor-β and IL-10.
Defects of these regulatory T cells have been identified in
blood and synovium of RA patients and may contribute to the
disease chronicity. Some of these defects are sensitive to the
control of inflammation with TNF-α inhibitors [26].
Chemokines and migration of immune cells
Chemokines are small chemoattractant proteins that are
produced by many cell types: leucocytes, DCs, mesenchymal
cells and endothelial cells. They induce cell migration with
various degrees of cell selectivity for target tissues.
Chemokines are subdivided into different groups according
to the position of cysteine residues. Among them, CXC
chemokines such as IL-8 mainly attract neutrophils to
inflammatory sites, whereas CC chemokines or β chemokines
act mainly on lymphocytes and monocytes. Strong expres-
sions of various chemokines (CCL2/monocyte chemoattrac-
tant protein-1, CCL3/macrophage inflammatory protein
[MIP]-1α, CCL4/MIP-1β and CCL5/RANTES) and their
receptors (CCR2, CCR1 and CCR5) have been reported in
RA synovium, and the list continues to grow [27]. This could
be a limitation for the control of RA with chemokine inhibitors.
Because DC migratory properties are critical to initiation of
immune responses, the expression of particular chemokines
that play a role in DC migration is of particular interest
(Figure 2). The β chemokine CCL20/MIP-3α and its receptor
CCR6 control the migration of different cell types to the RA
synovium [28]. They are detected in the lining layer, where
proinflammatory cytokines act on synoviocytes and in the
perivascular lymphocytic infiltrates [10]. The production of
CCL-20 is potently induced by synergistic interactions of the
inflammatory cytokines TNF, IL-1 and IL-17 [29]. CCL20, in
turn, is a chemotactic factor for Th17 cells and for immature
DCs, with both cell types expressing CCR6 [30]. The close
association between CCL20-producing cells and immature
CD1a+ DCs, identified using immunohistochemistry, suggests
a link between the accumulation of immature DCs and local
production of CCL20.
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Figure 2
Role of chemokines in the migration of DCs and T-cell subsets in RA synovitis. In response to local inflammation and production of proinflammatory
cytokines, after an unknown event CC chemokine receptor (CCR)6+ immature dendritic cells (DCs) and T-helper (Th)17 cells are attracted to the
synovium in response to local production of CC chemokine ligand (CCL)20 in the perivascular infiltrates and the lining layer. It is also possible that
CCR6+ cells migrate to the synovial fluid toward CCL20 expressed within the lining layer. The presence of mature DCs in synovium results from
the combined effects of cell interactions and cytokine microenvironment. Defects in production of differentiation factors such as IL-4 may favor a
relative accumulation of immature DCs. However, detection of CCL19 and CCL21 in perivascular infiltrates and vascular endothelium argues for a
direct migration of some CCR7+ mature DCs from blood into the synovium, where they can interact with lymphocytes, leading to potent local
activation. RA, rheumatoid arthritis.Conversely, CCL19, CCL21 and their associated receptor
CCR7 contribute to the accumulation of mature DCs in T-
cell-rich areas of lymphoid organs and to the formation of
germinal centres [31]. When paired samples of lymph nodes
and synovium were obtained from the same RA patients, a
key difference was observed. As opposed to the situation in
lymph nodes, CCL19 and CCL21, which control the
migration of mature DCs, were rarely expressed in RA syno-
vium and their associated receptor CCR7 was poorly expres-
sed [32]. This finding is consistent with the relative accumu-
lation of immature versus mature DCs in RA synovium.
Defects in DC maturation may then result from changes in
DC migration rather than defects in local maturation of DCs.
Acting on cell interactions for treatment
Recent knowledge of these cell interactions has provided
new concepts for the development of new immunomodu-
latory therapies. The first option is the physical or functional
destruction of a bridge between these interacting cells. An
example of such physical destruction is the use of B-cell-
targeted therapy using a CD20 monoclonal antibody
(rituximab). This leads to the physical destruction of B cells
clearly in blood but also in synovium [33]. Following such
ablation of B cells, their interactions with other cell types,
namely T cells, are affected. Thus, targeting B cells, which are
also APCs, is a way to disrupt interactions with T cells.
However, targeting of B cells with rituximab does not lead to
massive antibody reduction. This indicates the possible
contribution made by long-lived plasma cells, which are
insensitive to the effect of B-cell depletion [34]. Such
prolonged survival of plasma cells may result from inter-
actions with synoviocytes. As observed with TNF inhibitors,
treatment with rituximab is unable to provide long-term
control of the disease, although it takes often 1 year for
B cells to accumulate again in the synovium.
A second option for treatment is to target the functional
interactions between T cells and APCs. Abatacept
(CTLA4-Ig) can mimic one of the endogenous regulatory
pathways by reproducing the inhibitory effect of CTLA4. It
selectively modulates the co-stimulatory pathway of T-cell
activation by preventing the engagement of CD80/CD86 on
APCs with CD28 on T cells. In patients with RA, the selective
modulation of co-stimulation on T cells with abatacept is
effective in reducing chronic inflammation [35]. Its precise
mode of action in this context is unclear, but the effects could
result from a downstream downmodulation of inflammatory
cytokines. Of interest is the slower mode of action and better
long-term effect with abatacept than with cytokine inhibitors.
Such kinetics suggest that there is a possible effect on
restoration of functional regulatory mechanisms.
Conclusion
RA synovitis involves interactions between T cells and DCs.
Chemokine and cytokine networks play a key role in their
migration and maturation through the production of pro-
inflammatory Th1 and Th17 cytokines. Such an inflammatory
environment induces local cellular changes that can lead to
chronicity. All of these inflammatory conditions create a self-
sustaining inflammatory loop. Such knowledge about inter-
actions between T cells, DCs, and chemokine and cytokine
systems is now forming the basis for new anti-inflammatory
therapies that are better targeted.
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